PlumX Metrics
Embed PlumX Metrics

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease

Brain, ISSN: 1460-2156, Vol: 144, Issue: 2, Page: 515-527
2021
  • 108
    Citations
  • 0
    Usage
  • 131
    Captures
  • 12
    Mentions
  • 2
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    108
  • Captures
    131
  • Mentions
    12
    • News Mentions
      10
      • News
        10
    • Blog Mentions
      2
      • Blog
        2
  • Social Media
    2
    • Shares, Likes & Comments
      2
      • Facebook
        2

Most Recent Blog

Tau Immunotherapy for Alzheimer's Disease is Proving to be as Challenging as Amyloid Immunotherapy

Alzheimer's disease is characterized by the aggregation of first amyloid-β and then tau protein in later stages. It took many years and many attempts to produce immunotherapies capable of clearing amyloid-β from the brain, only to find that this doesn't in fact help patients to any great degree. Amyloid-β may be a side-effect of the causative mechanisms - such as infection, or chronic inflammation

Most Recent News

New Biomarkers Catch Tau Before It Tangles

Scientists characterize early stage tau aggregates and develop a CSF test to track them.

Article Description

Tau is a microtubule associated protein in the brain that aggregates in Alzheimer's disease to form pathological tangles and neurites. Insoluble tau aggregates composed of the microtubule binding region (MTBR) of tau are highly associated with the cognitive and clinical symptoms of Alzheimer's disease. In contrast, levels of soluble forms of tau, such as CSF total tau and phosphorylated tau-181 and tau-217, increase prior to tau aggregation in Alzheimer's disease, but these biomarkers do not measure the MTBR of tau. Thus, how CSF MTBR-tau is altered in Alzheimer's disease remains unclear. In this study, we used sequential immunoprecipitation and chemical extraction methods followed by mass spectrometry to analyse MTBR-tau species in Alzheimer's disease and control CSF. We quantified MTBR-tau-specific regions in the CSF and identified that species containing the region beginning at residue 243 were the most highly correlated with tau PET and cognitive measures. This finding suggests that CSF level of tau species containing the upstream region of MTBR may reflect changes in tau pathology that occur in Alzheimer's disease and could serve as biomarkers to stage Alzheimer's disease and track the development of tau-directed therapeutics.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know